Zealand Pharma A/S (OTCMKTS:ZLDPF) Short Interest Down 63.8% in June

Zealand Pharma A/S (OTCMKTS:ZLDPF) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 374,424 shares, a decrease of 63.8% from the May 31st total of 1,035,563 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily volume of 4,924 shares, the short-interest ratio is presently 76.0 days.

Zealand Pharma A/S Price Performance

OTCMKTS:ZLDPF opened at $42.89 on Friday. The firm’s 50 day simple moving average is $47.67 and its 200 day simple moving average is $55.68. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. Zealand Pharma A/S has a one year low of $35.93 and a one year high of $83.12. The company has a market cap of $3.07 billion, a PE ratio of 3.18 and a beta of 0.86.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. The firm had revenue of $5.33 million for the quarter, compared to analyst estimates of $2.81 million. On average, research analysts anticipate that Zealand Pharma A/S will post 2.37 earnings per share for the current year.

Analyst Ratings Changes

ZLDPF has been the topic of a number of research reports. William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Three investment analysts have rated the stock with a Strong Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.